CAJ | 학술논문

近年来，嵌合抗原受体（ CAR）修饰T细胞在治疗肿瘤中取得了很大进展。 CAR具有赋予T细胞更强的靶向性并能打破宿主免疫耐受状态等理论优势，在白血病、淋巴瘤中取得了不错的疗效。但由于实体肿瘤的脱靶效应、免疫细胞不易进入实体瘤内部等因素，该应用尚处于临床前期试验阶段。本文将CAR修饰T细胞应用于部分实体瘤的试验进行综述，以便于读者更全面的认识CAR修饰T细胞的应用。
근년래，감합항원수체（ CAR）수식T세포재치료종류중취득료흔대진전。 CAR구유부여T세포경강적파향성병능타파숙주면역내수상태등이론우세，재백혈병、림파류중취득료불착적료효。단유우실체종류적탈파효응、면역세포불역진입실체류내부등인소，해응용상처우림상전기시험계단。본문장CAR수식T세포응용우부분실체류적시험진행종술，이편우독자경전면적인식CAR수식T세포적응용。
In recent years, the researches on chimeric antigen receptor( CAR) engineered T lymphocytes in curing cancer have made great progresses. CAR has several technical advantages, such as endowing great targeting ability to CAR?engineered T cells, breaking the state of immune tolerance and so on, which make great progress in curing Hematology. Because of existed off?target effects of solid tumor and the poor penetration of immune cells into the tumor tissue, this application is still in phase I clinical trial. This paper will make a review of the application of CAR enjineered T lymphocyte to some solid tumor experiments.